Royalty Pharma RPRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $2.61B+4.9% | $2.49B+3.5% | $2.41B0.0% | $2.41B-10.9% | $2.7B-2.5% | ||
| $12.96M-38.9% | $21.23M-31.4% | $30.93M0.0% | $30.93M0.0% | $30.93M+56.3% | ||
| $2.15B+26.6% | $1.7B+16.2% | $1.46B-13.7% | $1.69B-30.1% | $2.42B-3.4% | ||
| -$2.6B-60.8% | -$1.61B-26.9% | -$1.27B+15.6% | -$1.51B+27.8% | -$2.09B+22.1% | ||
| $568.7M-53.7% | $1.23B+2.3% | $1.2B+4.3% | $1.15B+22.5% | $938.43M+309% | ||
| $153.52M-8.3% | $167.48M+5.9% | $158.17M+2.1% | $154.9M+5.4% | $146.98M+17.4% | ||
| -$2.02M-12.6% | -$1.79M-178,900% | -$1K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$501.33M-61.5% | -$310.33M— | —— | —— | —— | ||
| $311M+12.6% | $276.29M+2.2% | $270.42M+23.2% | $219.42M0.0% | $219.42M+37.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $20.64M+88.6% | $10.94M+486% | $1.87M+980% | $173K— | —— | ||
| $222.69M-22.7% | $288.14M-4.7% | $302.32M-6.5% | $323.37M+16.6% | $277.4M+17.4% | ||
| $115.88M+1.6% | $114.02M-0.4% | $114.43M-0.6% | $115.13M+0.7% | $114.29M+5.0% | ||
| $3.44B+2.6% | $3.35B+4.3% | $3.22B+2.9% | $3.13B+1.9% | $3.07B+2.8% | ||
| $4.32M+499% | $720K-20.7% | $908K-12.2% | $1.03M-19.2% | $1.28M-91.3% | ||
| $271.31M0.0% | $271.31M-7.6% | $293.6M0.0% | $293.6M+135% | $125M+66.7% | ||
| —— | —— | —— | —— | $66.93M+7.1% | ||
| $35.1M+1.1% | $34.72M+40.9% | $24.64M-50.0% | $49.29M-33.3% | $73.93M-25.0% | ||
| —— | —— | —— | —— | $510.55M— | ||
| $12.96M-38.9% | $21.23M-31.4% | $30.93M0.0% | $30.93M0.0% | $30.93M+56.3% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $387.39M+2.4% | $378.25M+0.2% | $377.57M+0.3% | $376.32M-0.5% | $378.02M+0.4% | ||
| $153.52M-8.3% | $167.48M+5.9% | $158.17M+2.1% | $154.9M+5.4% | $146.98M+17.4% | ||
| $348.25M-1.9% | $354.9M-0.6% | $356.95M+0.1% | $356.6M-0.8% | $359.3M-0.8% | ||
| $4.62M-18.9% | $5.7M-15.3% | $6.73M-13.2% | $7.75M+89.2% | $4.1M-6.0% | ||
| —— | —— | —— | $878K-0.1% | $879K+17.7% | ||
| -$2.02M-12.6% | -$1.79M-178,900% | -$1K— | —— | —— | ||
| $28.78M-16.1% | $34.31M-7.2% | $36.97M-20.1% | $46.26M-11.2% | $52.08M+12.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
